Novartis AG won U.S. approval for the company’s experimental sickle cell disease drug Adakveo.
OncoCyte Corporation, a developer of novel tests for the early diagnosis and management of lung cancer, announced a definitive agreement to acquire Razor Genomics.
Innovations in diabetes care go beyond new therapeutic classes. Pharmaceutical companies are continuing to invest in new technology to help improve diabetes treatment and patient adherence with progress ranging from artificial pancreases to smart insulin pens and pumps.
NEW YORK, March 22, 2019 /PRNewswire/ — A leading quality rating for the nation’s hospitals appears not to adequately account for the risks of undergoing certain procedures at certain hospitals, particularly joint replacement surgery, according to a new study by researchers at Hospital for Special Surgery (HSS) in New York City. The study, reported in the […]
The U.S. Centers for Medicare & Medicaid Services proposed Medicare coverage of approved CAR-T cell therapies that use the patient’s immune system to fight cancer.
Evidenced by the move to measure and reimburse providers based on the quality, as opposed to the quantity, of care delivered, the healthcare industry is shifting from a fee-for-service to an outcomes or value-based model.
Johnson & Johnson raised U.S. prices on around two dozen prescription drugs, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto, all among the company’s top-selling products.
The U.S. government, in an effort to increase pressure on drugmakers to lower costs for U.S. consumers, will propose requiring companies to include the price of Rx medicines in TV ads.
The Centers for Medicare & Medicaid Services proposed a change in the payment amount for new drugs under its Part B program, amid the Trump administration’s attempts to tackle escalating prices of drugs.
The U.S. government said it would increase by 3.4 percent on average 2019 payments to the health insurers that manage Medicare Advantage insurance plans for seniors and the disabled, a higher-than-expected rise reflecting a projection of higher medical cost growth.